More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
More than 5,000 women were interviewed about their eating habits from 1985 to 1991, and then researchers followed up with them 30 years later. The full study was published in Alzheimer’s and Dementia.
Even as TAVR continues to build momentum as the go-to treatment option for many patients, researchers are keeping a close eye on the long-term safety and effectiveness of SAVR.
Here is a list of all the late-breaking clinical trials being presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2023 annual meeting Oct. 23-26, 2023, in San Francisco.
New research is providing a broader understanding of how cardiovascular disease risk manifests following pregnancy. Having obesity before and during early pregnancy appears to be a strong indicator of risk for developing future cardiovascular disease and was significantly linked with adverse outcomes during pregnancy.
